Latest MS research news

Latest MS research news | 05 October 2012

Analysis of prognostic factors associated with longitudinally extensive transverse myelitis

In this prospective study, they analysed the clinical, radiological and genetic characteristics of a series of 23 patients presenting with inflammatory longitudinally extensive transverse myelitis (LETM).

From MSIF

Latest MS research news | 01 October 2012

Subcortical atrophy and cognition: Sex effects in MS

This Swedish study looked at the correlation between subcortical gray matter atrophy and cognition in the early stages (6 years post diagnosis) of relapsing-remitting MS.

From MSIF

Latest MS research news | 01 October 2012

Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

This study is a Phase II placebo-controlled, double-blind study, looking at the safety and efficacy of Lisdexamfetamine dimesylate (LDX) in people with MS with cognitive impairment.

From MSIF

Latest MS research news | 01 October 2012

Scoring treatment response in patients with relapsing-remitting MS

This study from Italy included two large independent databases of people with relapsing-remitting MS treated with interferon. The first dataset, the “training set”, consisted of 373 people with relapsing-remitting MS, from a randomised clinical trial, who were treated with interferon beta-1a.

From MSIF

Latest MS research news | 25 September 2012

No MRI evidence of cortical lesions in neuromyelitis optica

This collaborative imaging study aims to examine the presence of cortical lesions in neuromyelitis optica (NMO). The authors have used a double inversion recovery sequence for detection of cortical lesions which has now become a standard sequence for this purpose in studies of MS patients.

From MSIF

Latest MS research news | 25 September 2012

Placebo-controlled phase 3 study of oral BG-12 for relapsing MS

Data from this randomised, double-blind, placebo-controlled phase 3 study oral BG-12 in relapsing remitting MS (RRMS) shows a reduction in annualised relapse rate of approximately 50% compared to placebo.

From MSIF

Latest MS research news | 19 September 2012

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in MS

The research group from the Netherlands performed a prospective observational study of 73 people with MS treated with natalizumab. They measured serum natalizumab levels and antibody titres before the start of natalizumab treatment, at weeks 12 and 24 and then each year after natalizumab initiation.

From MSIF

Latest MS research news | 18 September 2012

Ginkgo biloba does not improve cognitive function in MS

The authors have evaluated the effects of ginkgo biloba on cognitive function in people with MS with impaired cognition. A treatment regimen of ginkgo 120 mg twice a day did not improve cognitive performance in persons with MS.

From MSIF

Latest MS research news | 17 September 2012

Neutralising antibodies are associated with a reduction of Interferon B efficacy during the treatment of Japanese MS patients

This multi-centre study from a research group in Japan examines the prevalence of neutralising antibodies (NAbs), in Japanese people with MS treated with Interferon B.

From MSIF

Latest MS research news | 13 September 2012

Automated determination of brain parenchymal fraction in MS

The authors from Sweden looked at brain atrophy as a manifestation of tissue damage in MS, using synthetic tissue mapping (SyMap).

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial